Crispr Therapeutics AG (NASDAQ:CRSP) Stock analysts at Oppenheimer issued their Q1 2020 EPS estimates for Crispr Therapeutics in a note issued to investors on Tuesday, November 12th. Oppenheimer analyst S. Tuerkcan forecasts that the company will post earnings per share of ($0.87) for the quarter. Oppenheimer has a Outperform rating and a $65.00 price target on the stock. Oppenheimer also issued estimates for Crispr Therapeutics FY2021 earnings at ($4.29) EPS, FY2022 earnings at ($4.70) EPS and FY2023 earnings at ($1.07) EPS.

CRSP has been the subject of a number of other reports. Piper Jaffray Companies restated an overweight rating on shares of Crispr Therapeutics in a research note on Monday, October 21st. BTIG Research upped their target price on Crispr Therapeutics from $51.00 to $59.00 and gave the company a positive rating in a research note on Tuesday, July 30th. Roth Capital upped their target price on Crispr Therapeutics from $50.00 to $65.00 in a research note on Tuesday, July 30th. Canaccord Genuity initiated coverage on Crispr Therapeutics in a research note on Friday, July 26th. They issued a buy rating and a $72.00 target price for the company. Finally, BidaskClub upgraded Crispr Therapeutics from a hold rating to a buy rating in a research note on Friday. Two research analysts have rated the stock with a sell rating, three have given a hold rating and twelve have given a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $57.95.

CRSP opened at $56.87 on Friday. The business has a 50 day moving average price of $43.31 and a 200 day moving average price of $44.57. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The firm has a market cap of $3.04 billion, a P/E ratio of -16.53 and a beta of 3.15. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $57.40.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million during the quarter, compared to analysts expectations of $6.32 million.

A number of large investors have recently made changes to their positions in CRSP. NEXT Financial Group Inc grew its position in Crispr Therapeutics by 915.0% in the third quarter. NEXT Financial Group Inc now owns 609 shares of the companys stock valued at $25,000 after acquiring an additional 549 shares during the period. Benjamin Edwards Inc. grew its position in Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the companys stock valued at $26,000 after acquiring an additional 268 shares during the period. Coastal Investment Advisors Inc. bought a new stake in Crispr Therapeutics in the third quarter valued at $26,000. US Bancorp DE grew its position in Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the companys stock valued at $29,000 after acquiring an additional 526 shares during the period. Finally, BSW Wealth Partners bought a new stake in Crispr Therapeutics in the second quarter valued at $39,000. Hedge funds and other institutional investors own 51.09% of the companys stock.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the companys stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the sale, the director now directly owns 7,500 shares in the company, valued at $412,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 21.40% of the companys stock.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Recommended Story: Penny Stocks, Risk and Reward Factors

Read this article:
Oppenheimer Weighs in on Crispr Therapeutics AG's Q1 2020 Earnings (NASDAQ:CRSP) - DFS Caller

Comments are closed.